Publications
161
Citations
7,684
Est. group size
~14
Recurring co-author estimate
Active years
16
Publishing since 2009
Jessica Kohlschmidt's research focuses on acute myeloid leukemia (AML) and related blood cancers, particularly studying genetic and molecular markers (such as chromosomal abnormalities and RNA profiles) that predict how patients will respond to treatment. Much of this work draws on data from large multi-center clinical trials to identify risk factors and treatment outcomes, including differences in care between academic and community medical centers and disparities across patient populations.
Publication output has been fairly steady to growing over the past decade, with a notable spike in 2023 following consistent yearly counts in the teens.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials
JCO Oncology Practice · 2023
- Data from Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia
2023
- Supplementary Methods; Supplementary Tables S1, S3; and Supplementary Figures S1-S2 from Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia
2023
- Supplementary Methods; Supplementary Tables S1, S3; and Supplementary Figures S1-S2 from Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia
2023
- Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia
Blood Advances · 2022
- Molecular Landscape in Acute Myeloid Leukemia (AML) Patients (pts) from Mexico As an Initial Study to Identify Healthcare Disparities in Hispanic Populations: Alliance for Clinical Trials in Oncology [Alliance]
Blood · 2022
- Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes
Proceedings of the National Academy of Sciences · 2021
- Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)
Blood Advances · 2021
- Adverse Outcomes in Acute Myeloid Leukemia Are Associated with Tumor Cell-Mediated Immunosuppression
Blood · 2021
- Immunosuppression and Outcomes in Acute Myeloid Leukemia
bioRxiv (Cold Spring Harbor Laboratory) · 2021
- Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801
Blood Advances · 2020
- Core‐binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure
International Journal of Laboratory Hematology · 2020
- New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461
UNC Libraries · 2020
- Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia
Molecular Cancer Therapeutics · 2019
- Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Blood Advances · 2018
- Blood×41
- Leukemia×16
- Blood Advances×13
- Nature Communications×4
- Haematologica×4
- Priyanka Mehta
Medicine · The Ohio State University
- Krzysztof Mrózek
Medicine · The Ohio State University
- Bhavana Bhatnagar
Medicine · The Ohio State University
- Deedra Nicolet
Medicine · The Ohio State University
- Ann‐Kathrin Eisfeld
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile